Author

Audrey L. Shaw

Observed names: A Shaw, A. Shaw, Audrey L Shaw, Audrey Lynn Shaw, Audrey Shaw, Shaw AL

Observed institutions: Saint Thomas West Hospital, Cedars-Sinai Medical Center, Dartmouth–Hitchcock Medical Center, Harvard University, University of California, San Francisco, Virginia Commonwealth University, University of Michigan, Center for Digestive and Liver Diseases, Nashville Medical Research Institute, Michigan Medicine, Syracuse VA Medical Center, Digestive Health Associates of Texas, Gilead Sciences (United States), Dr Falk Pharma (Germany), Salix Pharmaceuticals (United States), University of Pennsylvania

OpenAlex ID: A5079212875

Rifaximin Treatment in Hepatic Encephalopathy

2010 · Nathan M. Bass, Kevin D. Mullen, et al. · New England Journal of Medicine · 1,302

Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

2011 · Mark Pimentel, Anthony Lembo, et al. · New England Journal of Medicine · 1,035

PDF

Severe Hepatotoxicity Associated with Nevirapine Use in HIV‐Infected Subjects

2005 · Ian Sanne, Herve Mommeja‐Marin, et al. · The Journal of Infectious Diseases · 242

PDF

Pharmacogenetics of Nevirapine-Associated Hepatotoxicity: An Adult AIDS Clinical Trials Group Collaboration

2006 · D. W. Haas, J. A. Bartlett, et al. · Clinical Infectious Diseases · 145

PDF

Gut barrier dysfunction and microbial translocation in cancer cachexia

2013 · Gerald L. Klein, Bryon W. Petschow, et al. · Current Opinion in Supportive and Palliative Care · 95

Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects with Diarrhea-Predominant Irritable Bowel Syndrome

2013 · Dale Wilson, Malkanthi Evans, et al. · Clinical Medicine Insights Gastroenterology · 72

PDF

Safety and Efficacy of a New 3.3 g b.i.d. Tablet Formulation in Patients With Mild-to-Moderately-Active Ulcerative Colitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

2009 · Ellen J Scherl, Ronald Pruitt, et al. · The American Journal of Gastroenterology · 52

Prevention of Travelers' Diarrhea With Rifaximin in US Travelers to Mexico

2010 · Francisco Martinez‐Sandoval, Charles D. Ericsson, et al. · Journal of Travel Medicine · 44

Serum-derived bovine immunoglobulin/ protein isolate: postulated mechanism of action for management of enteropathy

2014 · Bryon Petschow, Bruce Burnett, et al. · Clinical and Experimental Gastroenterology · 41

PDF

Potential mechanisms of effects of serum‐derived bovine immunoglobulin/protein isolate therapy in patients with diarrhea‐predominant irritable bowel syndrome

2017 · Nelson Valentin, Michael Camilleri, et al. · Physiological Reports · 28

PDF

Dietary Requirement for Serum-Derived Bovine Immunoglobulins in the Clinical Management of Patients with Enteropathy

2014 · Bryon W. Petschow, Bruce P. Burnett, et al. · Digestive Diseases and Sciences · 26

PDF

Impact of serum-derived bovine immunoglobulin/protein isolate therapy on irritable bowel syndrome and inflammatory bowel disease: a survey of patient perspective

2017 · Audrey Shaw, Adam Tomanelli, et al. · Patient Preference and Adherence · 17

PDF

Absorption and safety of serum-derived bovine immunoglobulin/protein isolate in healthy adults

2016 · Audrey L Shaw, David W Mathews, et al. · Clinical and Experimental Gastroenterology · 17

PDF

Serum Bovine Immunoglobulins Improve Inflammation and Gut Barrier Function in Persons with HIV and Enteropathy on Suppressive ART

2019 · Netanya Sandler Utay, Anoma Somasunderam, et al. · Pathogens and Immunity · 15

PDF

475i Rifaximin Treatment for 2 Weeks Provides Acute and Sustained Relief Over 12 Weeks of IBS Symptoms in Non-Constipated Irritable Bowel Syndrome: Results From 2 North American Phase 3 Trials (Target 1 and Target 2)

2010 · Mark Pimentel, Anthony Lembo, et al. · Gastroenterology · 12

Endotoxin neutralization activity (ENA) of bovine plasma and bovine Immunoglobulin (IgG)‐rich fractions as compared to human plasma

2013 · Eric M Weaver, Gerald L Klein, et al. · The FASEB Journal · 10

195 Rifaximin Decreases Venous Ammonia Concentrations and Time-weighted Average Ammonia Concentrations Correlate With Overt Hepatic Encephalopathy (he) as Assessed by Conn Score in a 6-month Study

2010 · A. Sanyal, N. Bass, et al. · Journal of Hepatology · 10

PDF

66 Rifaximin Reduces the Risk of Hospitalizations in Patients with Previous Episodes of Hepatic Encephalopathy: Results from a Phase 3 Placebo-Controlled Trial

2009 · Guy Neff, Carroll B. Leevy, et al. · Gastroenterology · 6

Evaluation of oral serum-derived bovine immunoglobulins in HIV-infected patients with chronic idiopathic diarrhea

2017 · David M. Asmuth, John E. Hinkle, et al. · HIV Clinical Trials · 5

PDF

Once-Daily 1.5-G Granulated mesalamine Effectively Maintains Remission in Patients with Ulcerative Colitis Who Switch from Different 5-ASA Formulations

2008 · Gary Lichtenstein, Kunal Merchant, et al. · The American Journal of Gastroenterology · 5

Sa1218 Efficacy of Serum-Derived Bovine Immunoglobulin Protein Isolate (SBI) in Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

2013 · Dale Wilson, Eric Weaver, et al. · Gastroenterology · 3

PDF

Oral serum bovine immunoglobulin improves IBS-D symptoms analyzed from patient medical charts.

2017 · Larry Good, Audrey Shaw, et al. · 2

Oral serum bovine immunoglobulin improves IBS-D symptoms analyzed from patient medical charts.

2017 · Larry Good, Audrey Shaw, et al. · 2

PDF

T1204 Efficacy of Mesalamine Granules for Maintenance of Remission in Patients Recently Treated with Corticosteroids

2009 · Gary R. Lichtenstein, Kunal Merchant, et al. · Gastroenterology · 2

Safety Profile of Once-Daily 1.5-G Granulated mesalamine as Maintenance Therapy for Mild-to-Moderate Ulcerative Colitis

2008 · Salam Zakko, Uma Murthy, et al. · The American Journal of Gastroenterology · 2

Works count: 53

Citation count: 3,196

H-index: 14

I10-index: 17